BTF3 and cancer: As a decreased binding peak of BTF3 was located in the promoter region of CHD1L (Figure 2B) and CHD1L has been reported as an oncogene in CRC (Ji et al., 2013) and other cancer types (Chen et al., 2009, 2010, 2011; Li et al., 2013; Liu et al., 2016), we chose CHD1L as a target candidate.